Novartis’ Diovan Growth Bolstered By Awareness Program, Part D
This article was originally published in The Pink Sheet Daily
Executive Summary
The company reported double-digit sales growth for its top three products in the second quarter.
You may also be interested in...
Novartis Head Of Pharma Development James Shannon: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
The company is moving forward with a new drug development paradigm and its “category captainship” program.
Novartis Head Of Pharma Development James Shannon: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
The company is moving forward with a new drug development paradigm and its “category captainship” program.
Novartis/Chiron Deal To Close April 20
Novartis' acquisition of Chiron is set to close on April 20, the firms said April 19